Get the Stockscreener App
14.83
3.89%
-0.60
Wave Life Sciences Ltd stock is traded at $14.83, with a volume of 3.13M.
It is down -3.89% in the last 24 hours and down -19.92% over the past month.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$15.43
Open:
$15.28
24h Volume:
3.13M
Relative Volume:
0.49
Market Cap:
$2.75B
Revenue:
$93.95M
Net Income/Loss:
$-129.87M
P/E Ratio:
-16.48
EPS:
-0.9
Net Cash Flow:
$-202.88M
1W Performance:
-12.76%
1M Performance:
-19.92%
6M Performance:
+113.38%
1Y Performance:
+18.64%
1-Day Range:
$14.34
$15.78
1-Week Range:
$14.34
$19.50
52-Week Range:
$5.28
$21.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd
Sector
Industry
Phone
617-949-2900
Address
7 STRAITS VIEW, SINGAPORE
Compare WVE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
14.83 | 2.87B | 93.95M | -129.87M | -202.88M | -0.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-25 | Reiterated | Wedbush | Outperform |
| Dec-09-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-04-25 | Initiated | Canaccord Genuity | Buy |
| Jul-28-25 | Initiated | Oppenheimer | Outperform |
| Jul-16-25 | Initiated | Citigroup | Buy |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Wedbush | Outperform |
| Feb-25-25 | Initiated | Jefferies | Buy |
| Oct-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-27-24 | Resumed | JP Morgan | Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Sep-09-24 | Initiated | JP Morgan | Overweight |
| May-15-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Raymond James | Outperform |
| May-24-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Jul-15-19 | Initiated | Cowen | Market Perform |
| Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-07-18 | Initiated | Stifel | Buy |
| Jul-23-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Feb-15-17 | Initiated | H.C. Wainwright | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
| Dec-07-15 | Initiated | Jefferies | Buy |
| Dec-07-15 | Initiated | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd Stock (WVE) Latest News
Is Wave Life Sciences Ltd. (1U5) stock protected from inflationEarnings Trend Report & Real-Time Market Sentiment Reports - ulpravda.ru
Will Wave Life Sciences Ltd. stock outperform tech sector in 2025CPI Data & Daily Entry Point Trade Alerts - ulpravda.ru
How Wave Life Sciences Ltd. (1U5) stock benefits from digital adoptionEarnings Summary Report & Safe Entry Momentum Stock Tips - ulpravda.ru
Quarterly Risk: Is Wave Life Sciences Ltd. stock dividend yield sustainableMarket Growth Summary & Safe Capital Allocation Plans - ulpravda.ru
What technical charts say about Wave Life Sciences Ltd. stock2025 Momentum Check & Accurate Trade Setup Notifications - ulpravda.ru
Wave Life Sciences (WVE) Valuation In Focus As Obesity Data, Equity Raise And Conference Updates Draw Attention - simplywall.st
Is Wave Life Sciences Ltd. stock attractive for income investorsPrice Channel Trading & Unlock Patterns Humans Can’t See - ulpravda.ru
Will Wave Life Sciences Ltd. stock maintain growth storyStock Rotation Strategies & Interactive Charts for Smarter Trading - ulpravda.ru
Why Wave Life Sciences Ltd. stock is rated strong buyEx-Dividend Date Alerts & Use Smart Algorithms to Pick Better Stocks - ulpravda.ru
Raymond James raises WAVE Life Sciences stock price target to $26 By Investing.com - Investing.com South Africa
Raymond James raises WAVE Life Sciences stock price target to $26 - Investing.com India
Arrowhead siRNA data in obesity mark POC for adipose delivery - BioCentury
Is Wave Life Sciences’ (WVE) Obesity Bet and Extended Cash Runway Quietly Redefining Its Risk‑Reward Profile? - simplywall.st
HC Wainwright maintains a buy rating on Wave Life Sciences Ltd. (WVE) - MSN
Growth or Bubble? Decoding Wave Life Sciences’ Stock Rise - StocksToTrade
Wave Life Sciences stock gains after Arrowhead data supports INHBE mechanism - Investing.com UK
Wave Life Sciences (WVE) Sees Stock Rise Amid Positive Weight Lo - GuruFocus
Wave Life Sciences stock jumps 17% as obesity gene-silencing race heats up - TechStock²
WAVE Life Sciences (NASDAQ:WVE) Shares Gap UpWhat's Next? - MarketBeat
Wave Life Sciences (WVE) Rises Over 18% Following Market Activit - GuruFocus
Is Wave Life Sciences’ Stock a Hidden Gem? - timothysykes.com
Assessing Wave Life Sciences (WVE) Valuation After A Sharp Share Price Rebound - Yahoo Finance
Wave Life Sciences Ltd. (WVE) Stock Analysis: A Biotech Innovator with Over 110% Potential Upside - DirectorsTalk Interviews
Wave Life Sciences stock drops 8% as JPM Healthcare Conference looms; obesity data in focus - TechStock²
Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Los Angeles Daily NewsWave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference - FinancialContent
San Gabriel Valley Tribune - FinancialContent
Wave Life Sciences (WVE) stock slides 6% — what traders are watching next - TechStock²
Wave Life Sciences stock drops 6% as WVE traders size up next obesity data - TechStock²
WAVE Life Sciences (NASDAQ:WVE) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Wave Life Sciences stock tumbles 8.5% in first 2026 session as traders refocus on next WVE-007 readout - ts2.tech
WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 7.1%Here's What Happened - MarketBeat
Wave Life Sciences (WVE) Emerges as Obesity Treatment Contender, Oppenheimer Boosts Price Target - Finviz
Wave Life Sciences (WVE) emerges as obesity treatment contender, Oppenheimer boosts price target - MSN
WAVE Life Sciences Positioned Within Nasdaq Index Biotech Innovation - Kalkine Media
Moody Aldrich Partners LLC Lowers Stock Holdings in WAVE Life Sciences Ltd. $WVE - MarketBeat
15 Best Stocks Under $25 to Buy Now - Insider Monkey
Wave Life Sciences’ (WVE) RNA Obesity Drug WVE-007 Shows Potential to Match GLP-1 Efficacy Without Muscle Loss - Yahoo Finance
H.C. Wainwright Maintains A Buy Rating On Wave Life Sciences Ltd. (WVE) - Finviz
Mid Cap Stocks To Watch TodayDecember 8th - MarketBeat
Wave Life Sciences Ltd. (WVE) Stock Analysis: Uncovering the 76.93% Upside Potential for Investors - DirectorsTalk Interviews
Voya Investment Management LLC Raises Stock Position in WAVE Life Sciences Ltd. $WVE - MarketBeat
WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Wave Life Sciences (WVE) Stock Today: Obesity Drug Catalyst, $402.5M Financing, and What Investors Are Watching Next - ts2.tech
WAVE Life Sciences (STU:1U5) EV-to-OCF : -14.67 (As of Dec. 25, 2025) - GuruFocus
What New Catalysts Are Rewriting the Narrative for Wave Life Sciences? - Yahoo Finance
Behavioral Patterns of WVE and Institutional Flows - Stock Traders Daily
Wave Life Sciences (WVE) Is Up 11.7% After Early WVE-007 Fat-Loss DataWhat's Changed - simplywall.st
Wave Life Sciences (WVE) Stock: December 24, 2025 News Roundup, Analyst Forecasts, and What Investors Are Watching Next - ts2.tech
Oppenheimer and Truist lift Wave Life Sciences Ltd. (WVE) price targets after positive trial - MSN
Best Biotech Stocks To Keep An Eye OnDecember 8th - MarketBeat
Wave Life Sciences Ltd Stock (WVE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
4.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):